Recently, it has been shown that tumor-reactive CD8+ T cells can be expanded when co-cultured with tumor organoids and assessed for their anti-tumor responses, providing proof-of-concept for developing patient-specific T cell-based therapies (Dijkstra et al. 2018). Here, CD8A is linked to neoplasm.